Blackwell J Henry, Michaelides Iacovos N, Gibault Floriane
Hit Discovery, Discovery Sciences, R&D, AstraZeneca, Cambridge CB2 0AA, United Kingdom.
J Med Chem. 2025 Jun 12;68(11):10520-10539. doi: 10.1021/acs.jmedchem.5c00036. Epub 2025 May 5.
The deconstruction of known ligands to proteins into smaller, often fragment-sized components and subsequent regrowth from these leaner starting points has been shown to have interesting and useful application in medicinal chemistry. Such efforts can provide excellent start points for renewed hit-to-lead campaigns while assisting medicinal chemists in gaining a deeper understanding on the ligandability of a protein. Selected case-studies making strategic use of the deconstruction-reconstruction logic are examined herein, thus aiming to highlight the value of employing this approach in drug discovery programs.
将已知的蛋白质配体解构为更小的、通常为片段大小的成分,并从这些更精简的起始点进行后续重新构建,已被证明在药物化学中具有有趣且有用的应用。这些努力可为重新开展从活性分子到先导化合物的研究活动提供绝佳的起始点,同时帮助药物化学家更深入地了解蛋白质的配体结合能力。本文研究了一些战略性地运用解构-重构逻辑的案例,旨在突出在药物发现项目中采用这种方法的价值。